Compare Bristol-Myers Squibb Co (BMY) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Uber Technologies Inc — how do they compare? Bristol-Myers Squibb Co trades at $57.13 (market cap $121.18B), while Uber Technologies Inc trades at $72.55 (market cap $151.16B). The key difference: Uber Technologies Inc is the larger of the two by market cap, and Bristol-Myers Squibb Co pays a 4.25% dividend while Uber Technologies Inc pays none. Which is the better fit depends on your goals.
| BMY | UBER | |
|---|---|---|
Market Cap | $121.18B | $151.16B |
Sector | Health | Industrials |
52-Week High | $62.37 | $100.10 |
52-Week Low | $42.60 | $68.61 |
Enterprise Value | $157.12B | $157.49B |
Dividend Yield | 4.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Uber (UBER) trades at $72.08, down 3.3% over the past 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong revenue growth to $52.02B in 2025 and a net income of $10.05B, though Q4 2025 earnings missed expectations. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Madrid and Munich, alongside cost-cutting measures such as HR layoffs and AI spending caps.
The outlook remains positive with an 81.67% analyst buy rating and a consensus price target of $108.92, suggesting significant upside. Key risks include execution challenges in autonomous driving, competitive pressures in key markets like India, and potential regulatory hurdles. Investors should weigh strong fundamentals against evolving industry dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
